# OnCo record akt (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/akt/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "akt" ;
  schema:name "AKT"@en ;
  schema:description "AKT is a central survival kinase downstream of PI3K, blocked by capivasertib in breast and now prostate cancer."@en ;
  schema:url <https://onco.cc/targets/akt/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Protein_kinase_B> ;
  owl:sameAs <http://www.wikidata.org/entity/Q423650> ;
  schema:citation <https://en.wikipedia.org/wiki/Protein_kinase_B> ;
  onco:tag "kinase" ;
  schema:alternateName "AKT1/2/3" ;
  onco:targetClass "kinase" ;
  onco:related <https://onco.cc/biomarkers/akt1-e17k/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/ipatasertib/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/aml-signalling/>, <https://onco.cc/pathways/cml-signalling/>, <https://onco.cc/pathways/melanoma-signalling/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/prostate-cancer-signalling/>, <https://onco.cc/pathways/sclc-signalling/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/>, <https://onco.cc/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/> .